ORAPRED ODT
Details
- Status
- Prescription
- First Approved
- 2006-06-01
- Routes
- ORAL
- Dosage Forms
- TABLET, ORALLY DISINTEGRATING
ORAPRED ODT Approval History
What ORAPRED ODT Treats
10 indicationsORAPRED ODT is approved for 10 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Allergic Conditions
- Atopic Dermatitis
- Drug Hypersensitivity
- Allergic Rhinitis
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative Erythroderma
Drugs Similar to ORAPRED ODT
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ORAPRED ODT FDA Label Details
ProIndications & Usage
FDA Label (PDF)Orapred ODT (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: Orapred ODT is a corticosteroid indicated as an anti-inflammatory or immunosuppressive agent for certain allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, specific infectious diseases or conditions and organ transplantation for the treatment of certain endocrine conditions for palliation of certain neoplastic conditions 1.1 Allergic Conditions Control of severe or incapacitating al...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.